Light AI Inc. Financial Results Overview
Light AI Inc. has reported remarkable financial results for the three and nine months ended September 30, 2025. As a leading healthcare technology company focused on artificial intelligence health diagnostic solutions, Light AI has demonstrated substantial progress in software development and commercialization efforts. Financial information is presented in Canadian dollars and adheres to International Financial Reporting Standards.
Recent Highlights of Financial Performance
During the third quarter of 2025, Light AI's total operating expenses, excluding interest, depreciation, and non-cash share compensation, amounted to $2.2 million. This shows a significant decrease when compared to the previous quarter's operating expenses of $4.0 million. In the same period last year, the operating expenses stood at $1.9 million, indicating a cautious yet strategic investment in growth.
Non-Cash Share Based Compensation Expenses
For the quarter, the company recognized a total non-cash share-based compensation expense of $3.4 million, primarily due to stock options and deferred share units granted at the company's annual general meeting. This reflects an increase from $0.1 million in the previous quarter, demonstrating the company's commitment to incentivizing its growth-focused strategies.
Strategic Investments in Development
A substantial portion of the cash-based operating expenses during Q3 2025 was for product development. The company allocated $1.2 million toward research and development, showcasing a minor reduction from $1.4 million in Q2 2025, yet an increase from $0.7 million in Q3 2024. Strategic marketing and investor relations initiatives represented approximately $0.7 million in expenses for the reporting quarter.
Long-Term Financial Outlook
For the nine months leading up to September 30, 2025, total operating expenses, exclusive of interest, amounted to $10.4 million. This period experienced a dramatic increase from $5.2 million year-over-year due to heightened marketing costs and investments in product development.
Company's Vision and Market Potential
"Light AI continues to make meaningful strides in developing our diagnostic software," stated Peter Whitehead, CEO of Light AI. The company aims to leverage its first-mover advantage and patented technology to tap into significant market opportunities while navigating regulatory processes effectively.
Financial Health and Asset Management
As of September 30, 2025, Light AI had cash reserves of $7.6 million and total assets amounting to $8.5 million. This reflects a decrease from $15.2 million in cash and $17.1 million in total assets as of the end of December 2024. The company successfully closed an offering, obtaining gross proceeds of $1,516,350 from issuing 2,757,000 units at $0.55 each.
Understanding Adjusted Working Capital
Light AI reported an adjusted working capital of $6.8 million, down from $14.6 million in December 2024. This metric offers insight into the company's operating liquidity and efficiency in managing its resources.
About Light AI Inc.
Light AI Inc. specializes in developing AI-driven health screening and diagnostic solutions. The company’s innovative platform applies advanced algorithms to smartphone images to identify medical conditions swiftly, marking a breakthrough in patient care and healthcare delivery.
Frequently Asked Questions
What are Light AI's main business focus areas?
Light AI focuses on developing AI-based health diagnostic solutions that leverage smartphone technology for rapid analysis of medical conditions.
How much did Light AI spend on research and development in Q3 2025?
The company spent $1.2 million on research and development during the third quarter of 2025.
What is the current cash position of Light AI?
As of September 30, 2025, Light AI reported cash reserves of $7.6 million.
What was the total operating expense for Light AI in 2025?
Total operating expenses for the nine months ended September 30, 2025, were $10.4 million.
How is Light AI planning to use its recent funding?
Light AI plans to allocate its recent funding towards product development and expanding its marketing and investor relations initiatives.
